Intra-Cellular Therapies Stock (NASDAQ: ITCI)

Dernières nouvelles pour Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Intra-Cellular Therapies

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies Inc. - Common Stock

Intra-Cellular Therapies Inc

<p>On Tuesday, <strong>Intra-Cellular Therapies, Inc. </strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) reported results from Study 304 of lumateperone 42 mg for the prevention of relapse in adult <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/g41740754/intra-cellular-therapies-announces-positive-topline-results-in-phase-3-trial-evaluating-caplyta-fo" rel="noreferrer noopener">patients with schizophrenia</a>.</p>
<p>On the primary endpoint, the time to relapse during the double-blind treatment phase was significantly longer in patients receiving lumateperone than in those receiving placebo (p=0.0002).</p>
<p>There were 18 relapses (16.4%) in the lumateperone group versus 44 relapses (38.6%) in the placebo group.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/m-a/24/08/40586451/regulators-expected-to-approve-innovative-schizophrenia-treatment-from-bristol-myers-karuna" rel="noreferrer noopener">Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna</a></strong></p>
<p>Treatment with lumateperone was associated with a 63% reduction in risk of relapse versus placebo.</p>
<p>Lumateperone also met the key secondary endpoint, time to all-cause discontinuation during the double-blind phase (p=0.0007).</p>
<p>Lmateperone was generally safe and well tolerated. The most commonly reported adverse event observed at a rate greater than or equal to 5% and twice the placebo rate was headache.</p>
<p>&#8220;Schizophrenia is a chronic, serious mental illness characterized by the occurrence of acute psychotic episodes that cumulatively worsen disease prognosis. The control of symptoms and the prevention of relapses is critical to improving long-term patient outcomes. We are very pleased that the results from Study 304, a randomized withdrawal trial, demonstrated efficacy along with favorable safety and tolerability which support the benefit of continued long-term treatment with lumateperone,&#8221; said Dr. <strong>Suresh Durgam</strong>, executive vice president and chief medical officer of Intra-Cellular Therapies.</p>
<p>Caplyta (lumateperone) is indicated in adults for schizophrenia and depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate.</p>
<p>Earlier this year, data from <a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38275710/intra-cellular-stock-rallies-on-successful-late-stage-depression-treatment-study" rel="noreferrer noopener">Studies 501</a> and 502 of lumateperone 42 mg as adjunctive therapy to antidepressants for major depressive disorder showed a statistically significant and clinically meaningful reduction in the Montgomery and Asberg Depression Rating&nbsp;Scale total score compared <a target="_blank" href="https://www.benzinga.com/general/biotech/24/06/39382029/intra-cellular-therapies-highlights-successful-data-from-second-depression-study" rel="noreferrer noopener">to placebo at Week 6</a>.</p>
<p><strong>Price Action:</strong> ITCI stock is up 0.72% at $86.79 at last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/earnings/24/11/41748807/thomson-reuters-q3-earnings-legal-corporate-segments-enjoy-revenue-boost-as-ceo-highlights-ai-inves" target="_blank" rel="noreferrer noopener">Thomson Reuters Q3 Earnings: Legal, Corporate Segments Enjoy Revenue Boost As CEO Highlights AI Investment</a></strong></li>
</ul>
<p><em>Photo: Shutterstock</em></p>


Biotech

News

Health Care

General

ITCI

Intra-Cellular Therapies' Treatment Reduces Schizophrenia Relapse Risk 63%

<p>On the primary endpoint, time to relapse during the double-blind treatment phase was significantly longer in patients receiving lumateperone compared to those receiving placebo (p=0.0002). There were 18 relapses (16.4%) in the lumateperone group versus 44 relapses (38.6%) in the placebo group. Treatment with lumateperone was associated with a 63% reduction in risk of relapse versus placebo (hazard ratio [95% CI] = 0.37, [0.22, 0.65]).</p>
<p>Lumateperone also met the key secondary endpoint, time to all cause discontinuation during the double-blind phase (p=0.0007).</p>
<p><br /><br />&nbsp;</p>


Intra-Cellular Therapies Reports Results From Study 304 Evaluating Lumateperone 42 Mg For The Prevention Of Relapse In Adult Patients With Schizophrenia; Says Study Showed Efficacy Along With Favorable Safety And Tolerability

<p>In the last three months, 15 analysts have published ratings on Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), offering a diverse range of perspectives from bullish to bearish.</p>
<p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">9</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Intra-Cellular Therapies, revealing an average target of $100.93, a high estimate of $130.00, and a low estimate of $74.00. This current average has increased by 2.78% from the previous average price target of $98.20. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730736038_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Intra-Cellular Therapies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$89.00</td>
<td>$81.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jeffrey Hung</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$92.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Intra-Cellular Therapies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Intra-Cellular Therapies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Intra-Cellular Therapies's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intra-Cellular Therapies analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Intra-Cellular Therapies</h2>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>Intra-Cellular Therapies's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Intra-Cellular Therapies displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>39.23%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Intra-Cellular Therapies's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of <strong>-15.03%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Intra-Cellular Therapies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-2.3%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Intra-Cellular Therapies's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-1.99%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Intra-Cellular Therapies's debt-to-equity ratio is below the industry average. With a ratio of <b>0.02</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Demystifying Intra-Cellular Therapies: Insights From 15 Analyst Reviews

<p>JP Morgan  analyst Jessica Fye   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and raises the price target from $81 to $89.</p>


Price Target

JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $89

<p>Needham  analyst Ami Fadia   reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Buy and maintains $100 price target.</p>


Reiteration

Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $100 Price Target

WIIM

Intra-Cellular Therapies shares are trading higher after the company reported better-than-expected Q3 revenue results and raised its FY24 net product sales guidance. Also, Needham reiterated a Buy rating on the stock.

<p><strong>Fiscal 2024 Financial Outlook</strong></p>
<ul>
<li>Raised CAPLYTA full year 2024 net product sales guidance range to $665 to $685&nbsp;million.</li>
<li>Narrowed full year 2024 SG&amp;A expense guidance range to $490 to&nbsp;$510&nbsp;million and full year 2024 R&amp;D expense guidance range to $220 to&nbsp;$230&nbsp;million.</li>
</ul>


Earnings

Guidance

CAPLYTA Raised 2024 Net Product Sales Guidance Range To $665M-$685M From $650M-$680M Vs .$66.573M Estimate

<p>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0.20) by 25 percent.  The company reported quarterly sales of $175.375 million which beat the analyst consensus estimate of $172.352 million by 1.75 percent.  This is a 39.00 percent increase over sales of $126.173 million the same period last year.</p>


Earnings Beats

Earnings Misses

Intra-Cellular Therapies Q3 2024 GAAP EPS $(0.25) Misses $(0.20) Estimate, Sales $175.375M Beat $172.352M Estimate

<p>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) will release its quarterly earnings report on Wednesday, 2024-10-30. Here's a brief overview for investors ahead of the announcement.</p>
<p>Analysts anticipate Intra-Cellular Therapies to report an <strong>earnings per share</strong> (EPS) of $-0.19.</p>
<p>The market awaits Intra-Cellular Therapies's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.</p>
<p>It's important for new investors to understand that guidance can be a significant driver of stock prices.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the last quarter, the company reported an EPS beat by $0.03, leading to a 1.07% increase in the share price on the subsequent day.</p>
<p>Here's a look at Intra-Cellular Therapies's past performance and the resulting price change:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.19</td>
<td>-0.33</td>
<td>-0.43</td>
<td>-0.56</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.16</td>
<td>-0.16</td>
<td>-0.30</td>
<td>-0.25</td>
</tr>
<tr>
<td><strong>Price Change %</strong></td>
<td>1.0%</td>
<td>-6.0%</td>
<td>-2.0%</td>
<td>5.0%</td>
</tr>
</tbody>
</table>
</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730210633_0.png" alt="eps graph" /></p>
<h3>Intra-Cellular Therapies Share Price Analysis</h3>
<p>Shares of Intra-Cellular Therapies were trading at $76.82 as of October 28. Over the last 52-week period, shares are up 52.2%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. </p>
<h3>Analysts' Take on Intra-Cellular Therapies</h3>
<p>Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Intra-Cellular Therapies.</p>
<p>A total of 12 analyst ratings have been received for Intra-Cellular Therapies, with the consensus rating being Outperform. The average one-year price target stands at $102.08, suggesting a potential 32.88% upside.</p>
<h3>Peer Ratings Comparison</h3>
<p>The analysis below examines the analyst ratings and average 1-year price targets of Jazz Pharmaceuticals, Elanco Animal Health and Catalent, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.</p>
<ul>
<li>Jazz Pharmaceuticals received a Outperform consensus from analysts, with an average 1-year price target of $171.67, implying a potential 123.47% upside.</li>
<li>Elanco Animal Health is maintaining an Outperform status according to analysts, with an average 1-year price target of $19.0, indicating a potential 75.27% downside.</li>
<li>Analysts currently favor an Neutral trajectory for Catalent, with an average 1-year price target of $63.5, suggesting a potential 17.34% downside.</li>
</ul>
<h3>Insights: Peer Analysis</h3>
<p>The peer analysis summary outlines pivotal metrics for Jazz Pharmaceuticals, Elanco Animal Health and Catalent, demonstrating their respective standings within the industry and offering valuable insights into their market positions and comparative performance.</p>
<p>
<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Intra-Cellular Therapies</td>
<td>Outperform</td>
<td>46.44%</td>
<td>$149.92M</td>
<td>-1.86%</td>
</tr>
<tr>
<td>Jazz Pharmaceuticals</td>
<td>Outperform</td>
<td>6.95%</td>
<td>$913.92M</td>
<td>4.52%</td>
</tr>
<tr>
<td>Elanco Animal Health</td>
<td>Outperform</td>
<td>12.02%</td>
<td>$689M</td>
<td>-0.83%</td>
</tr>
<tr>
<td>Catalent</td>
<td>Neutral</td>
<td>23.32%</td>
<td>$384M</td>
<td>0.64%</td>
</tr>
</tbody>
</table>
</p>
<p>Key Takeaway:</p>
<p>Intra-Cellular Therapies ranks at the bottom for Revenue Growth among its peers. It also has the lowest Gross Profit margin. The company's Return on Equity is negative, indicating lower profitability compared to others. Overall, Intra-Cellular Therapies lags behind its peers in key financial metrics.</p>
<h3>Get to Know Intra-Cellular Therapies Better</h3>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>Financial Insights: Intra-Cellular Therapies</h3>
<p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Intra-Cellular Therapies's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of <strong>46.44%</strong>. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-10.06%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Intra-Cellular Therapies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-1.86%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Intra-Cellular Therapies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-1.57%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Intra-Cellular Therapies's debt-to-equity ratio is below the industry average. With a ratio of <b>0.02</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/earnings"><strong>To track all earnings releases for Intra-Cellular Therapies visit their earnings calendar on our site.</strong></a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Earnings Preview For Intra-Cellular Therapies

<p>Morgan Stanley  analyst Jeffrey Hung   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and raises the price target from $92 to $95.</p>


Morgan Stanley Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $95

<p>12 analysts have shared their evaluations of Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $102.5, a high estimate of $130.00, and a low estimate of $74.00. This current average has increased by 3.02% from the previous average price target of $99.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1728061459_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Intra-Cellular Therapies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$108.00</td>
<td>$106.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Intra-Cellular Therapies. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>For valuable insights into Intra-Cellular Therapies's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intra-Cellular Therapies analyst ratings.</strong></a></p>
<h2>All You Need to Know About Intra-Cellular Therapies</h2>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>Breaking Down Intra-Cellular Therapies's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Revenue Growth:</strong> Intra-Cellular Therapies displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately <strong>46.44%</strong>. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>-10.06%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Intra-Cellular Therapies's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-1.86%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Intra-Cellular Therapies's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-1.57%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Intra-Cellular Therapies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.02</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Deep Dive Into Intra-Cellular Therapies Stock: Analyst Perspectives (12 Ratings)

<p>RBC Capital  analyst Brian Abrahams   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Outperform and raises the price target from $106 to $108.</p>


RBC Capital Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $108

<p>Cantor Fitzgerald  analyst Charles Duncan   reiterates Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and maintains $130 price target.</p>


Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $130 Price Target

<p>In the latest quarter, 16 analysts provided ratings for Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Intra-Cellular Therapies, presenting an average target of $97.06, a high estimate of $130.00, and a low estimate of $74.00. Marking an increase of 3.26%, the current average surpasses the previous average price target of $94.00. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1725645611_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A comprehensive examination of how financial experts perceive Intra-Cellular Therapies is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Charles Duncan</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$92.00</td>
<td>$68.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$81.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$106.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Raises</td>
<td>Overweight</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$79.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Corinne Jenkins</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$74.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$94.00</td>
</tr>
<tr>
<td>Ashwani Verma</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$83.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$103.00</td>
<td>$103.00</td>
</tr>
<tr>
<td>Graig Suvannavejh</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$100.00</td>
<td>$96.00</td>
</tr>
<tr>
<td>Sumant Kulkarni</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$113.00</td>
<td>$107.00</td>
</tr>
<tr>
<td>Ami Fadia</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$94.00</td>
<td>$90.00</td>
</tr>
<tr>
<td>Charles Duncan</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Jessica Fye</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$78.00</td>
<td>$75.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Intra-Cellular Therapies. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Intra-Cellular Therapies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>To gain a panoramic view of Intra-Cellular Therapies's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ITCI/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Intra-Cellular Therapies analyst ratings.</strong></a></p>
<h2>Unveiling the Story Behind Intra-Cellular Therapies</h2>
<p>Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.</p>
<h3>A Deep Dive into Intra-Cellular Therapies's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Intra-Cellular Therapies showcased positive performance, achieving a revenue growth rate of <strong>46.44%</strong> as of 30 June, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Intra-Cellular Therapies's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-10.06%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of <strong>-1.86%,</strong> the company may need to address challenges in generating satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Intra-Cellular Therapies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-1.57%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.02</strong>, Intra-Cellular Therapies adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>What Are Analyst Ratings?</h2>
<p>Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Expert Ratings For Intra-Cellular Therapies

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page.</a></p>
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/585939c1ee7bf600010fe945/nigel-coe">Wolfe Research analyst Nigel Coe</a> upgraded the rating for <strong>Eaton Corporation plc</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ETN#NYSE">ETN</a>) from Underperform to Peer Perform. Eaton shares fell 1.1% to close at $285.72 on Thursday. <a href="https://www.benzinga.com/quote/ETN/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Deutsche Bank analyst Nicole Deblase upgraded <strong>Hubbell Incorporated</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUBB#NYSE">HUBB</a>) from Hold to Buy and raised the price target from $431 to $441. Hubbell shares fell 1.2% to close at $370.42 on Thursday. See how other analysts view this stock.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5ffc5e0662ba1f0001bb0ac5/nick-lai">JP Morgan analyst Nick Lai </a>upgraded the rating for<strong> NIO Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) from Neutral to Overweight and raises the price target from $5.3 to $8. NIO shares gained 14.4% to close at $4.85 on Thursday. <a href="https://www.benzinga.com/quote/nio/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Piper Sandler analyst Charles Duncan upgraded <strong>Intra-Cellular Therapies, Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Neutral to Overweight and boosted the price target from $68 to $92. Intra-Cellular Therapies shares declined 0.3% to close at $72.42 on Thursday. S<a href="https://www.benzinga.com/quote/itci/analyst-ratings">ee how other analysts view this stock.</a></li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/630f381cec9f420001742995/benjamin-budish">Barclays analyst Benjamin Budish</a> upgraded the rating for <strong>Robinhood Markets, In</strong>c. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>) from Underweight to Equal-Weight and raised the price target from $18 to $20. Robinhood shares gained 2.9% to close at $19.67 on Thursday. <a href="https://www.benzinga.com/quote/hood/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying HOOD stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="521" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-1024x521.png" alt="" class="wp-image-534479" style="width:643px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-1024x521.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12-768x391.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/09/06085850/image-1-12.png 1311w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>


Upgrades

Pre-Market Outlook

Markets

HOOD

HUBB

This Robinhood Analyst Is No Longer Bearish; Here Are Top 5 Upgrades For Friday

<p>Piper Sandler  analyst Charles Duncan   upgrades Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) from Neutral to Overweight and raises the price target from $68 to $92.</p>


Piper Sandler Upgrades Intra-Cellular Therapies to Overweight, Raises Price Target to $92

<p>JP Morgan  analyst Jessica Fye   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Overweight and raises the price target from $79 to $81.</p>


JP Morgan Maintains Overweight on Intra-Cellular Therapies, Raises Price Target to $81

<p>RBC Capital  analyst Brian Abrahams   maintains Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) with a Outperform and lowers the price target from $107 to $106.</p>


RBC Capital Maintains Outperform on Intra-Cellular Therapies, Lowers Price Target to $106

Intra-Cellular jumps on Q3 beat as Caplyta outlook brightens

Intra-Cellular Therapies, Inc. (ITCI) Q3 2024 Earnings Call Transcript

Morgan Stanley analyst Jeffrey Hung has maintained their bullish stance on ITCI stock, giving a Buy rating yesterday. Jeffrey Hung has given his Bu...

Intra-Cellular Therapies' Strong Growth Potential and Strategic Positioning Earns 'Buy' Rating

Intra-Cellular Therapies ( ($ITCI) ) has realeased its Q3 earnings. Here is a breakdown of the information Intra-Cellular Therapies presented to it...

Intra-Cellular Therapies Reports Strong Q3 Growth

Bank of America Securities analyst Jason Gerberry has reiterated their bullish stance on ITCI stock, giving a Buy rating today. Jason Gerberry has ...

Promising Growth and Undervaluation: Caplyta's Potential in MDD and BPD Drives Buy Rating

Cantor Fitzgerald raised the firm's price target on Intra-Cellular (ITCI) to $135 from $130 and keeps an Overweight rating on the shares. Intra-Cel...

Intra-Cellular price target raised to $135 from $130 at Cantor Fitzgerald

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Vir Biotechnology (VIR – Research Report), Intra-C...

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (VIR), Intra-Cellular Therapies (ITCI) and Neurocrine (NBIX)

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Intra-Cellular (ITCI) Therapies announced positive results from Study 304 evaluating the efficacy and safety of lumateperone 42 mg for the preventi...

Intra-Cellular announces results from Study 304 on lumateperone

Intra-Cellular meets main goal in late stage trial for its schizophrenia treatment

ANAB

BMRN

EXEL

GLYC

HOTH

INCY

NBIX

RGLS

SPRO

Press Releases

Intra-Cellular Therapies to Host Second Quarter 2024 Financial Results Conference Call and Webcast

Intra-Cellular Therapies Reports Second Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 CAPLYTA Sales Guidance

Management

Intra-Cellular Therapies Announces Appointment of Sanjeev Narula as Chief Financial Officer

Intra-Cellular Therapies to Present at the Canaccord Genuity 44th Annual Growth Conference

Intra-Cellular Therapies to Present at Three Upcoming Investor Conferences

Intra-Cellular Therapies Announces Presentations at the 2024 European College of Neuropsychopharmacology Congress

Intra-Cellular Therapies to Host Third Quarter 2024 Financial Results Conference Call and Webcast

Intra-Cellular Therapies Reports Third Quarter 2024 Financial Results, Provides Corporate Update and Raises 2024 Caplyta Sales Guidance

Intra-Cellular Therapies Announces Positive Topline Results in Phase 3 Trial Evaluating CAPLYTA for the Prevention of Relapse in Patients with Schizophrenia

Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress

Axsome Therapeutics

AstraZeneca PLC - American Depositary Shares

AstraZeneca

Bristol-Myers Squibb Company Common Stock

Bristol-Myers Squibb

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Catalent

Elanco Animal Health Incorporated Common Stock

Elanco Animal Health

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

GSK plc American Depositary Shares (Each representing two Ordinary Shares)

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Jazz Pharmaceuticals plc - Ordinary Shares

Jazz Pharmaceuticals

Johnson & Johnson

Eli Lilly

Merck & Co

Novo Nordisk

Novartis

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Pfizer

Dr. Reddy's Laboratories Ltd Common Stock

Dr Reddy's Laboratories

Royalty Pharma plc - Class A Ordinary Shares

Royalty Pharma

Sanofi

Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)

Comments

Intra-Cellular Therapies

Actualités

Dernières nouvelles pour Intra-Cellular Therapies (NASDAQ:ITCI) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL